Puma Biotechnology, Inc. Appoints Michael P. Miller to its Board
February 27, 2018 at 04:06 pm EST
Share
On February 23, 2018, Michael P. Miller was appointed to the Board of Directors of Puma Biotechnology, Inc. Mr. Miller will serve on the Board for a term expiring at the 2018 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal. Mr. Miller has served as the Executive Vice President U.S. Commercial of Jazz Pharmaceuticals plc, since May 2017 and as its Senior Vice President U.S. Commercial from April 2014 until May 2017.
Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4 It also engaged in the development and commercialization of, alisertib. Alisertib is a selective, small molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.
PUMA BIOTECHNOLOGY, INC. 
